Doheny, D., Manore, S., Sirkisoon, S. R., Zhu, D., Aguayo, N. R., Harrison, A., . . . Lo, H. (2022). An FDA-Approved Antifungal, Ketoconazole, and Its Novel Derivative Suppress tGLI1-Mediated Breast Cancer Brain Metastasis by Inhibiting the DNA-Binding Activity of Brain Metastasis-Promoting Transcription Factor tGLI1. Cancers, 14(17), 4256-4276. https://doi.org/10.3390/cancers14174256

Doheny, Daniel, et al. "An FDA-Approved Antifungal, Ketoconazole, and Its Novel Derivative Suppress TGLI1-Mediated Breast Cancer Brain Metastasis by Inhibiting the DNA-Binding Activity of Brain Metastasis-Promoting Transcription Factor TGLI1." Cancers 14, no. 17 (2022): 4256-4276. https://doi.org/10.3390/cancers14174256.

Doheny, Daniel, et al. "An FDA-Approved Antifungal, Ketoconazole, and Its Novel Derivative Suppress TGLI1-Mediated Breast Cancer Brain Metastasis by Inhibiting the DNA-Binding Activity of Brain Metastasis-Promoting Transcription Factor TGLI1." Cancers, vol. 14, no. 17, 2022, pp. 4256-4276, https://doi.org/10.3390/cancers14174256.